{"database": "lobbying", "table": "lobbying_activities", "rows": [[2472653, "5552821e-1ea2-44ea-892f-6702e326aa00", "Q2", "KING & SPALDING LLP", 21632, "SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)", 2020, "second_quarter", "PHA", "Issues related to drug pricing and six protected classes", "HOUSE OF REPRESENTATIVES", 60000, null, 0, 0, "2020-07-17T14:33:08.243000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2472653"], "units": {}, "query_ms": 0.3245699917897582, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}